Publications
& Policy

In this paper Invest Europe argued against an interpretation of AIFMD leverage rules that would capture portfolio company debt as leverage of the fund.

Invest Europe member firm Revaia has released the second edition of its European ESG Data Benchmark. Using 2024 data from European tech and growth companies, the report compares results with 2023 to assess progress and resilience in the face of growing ESG scrutiny.

During this webinar we unpacked the key elements of the review and discussed what they could mean in practice for PE/VC fund managers and investors.

The report, by ADC Consulting and Dansk Bio, highlights the EU's lagging biotech sector compared to the US, driven by major funding gaps (especially pension fund investment), regulatory hurdles, and weak commercialization ecosystems. It calls for urgent action, including harmonized regulations, a unified stock exchange, and fostering better translation from research to market, to unlock Europe's potential and prevent further talent drain to the US.

With key data contributions from Invest Europe, the 2025 edition of Atomico's SOET report highlights a powerful shift: Europe is becoming a global tech powerhouse.

Invest Europe welcomes the opportunity to contribute to the review of the Foreign Subsidies Regulation (FSR). As the association representing private equity (PE), venture capital (VC), and infrastructure fund managers and their investors, we want to highlight that the sector is disproportionately affected by the current FSR regime.

Too many PE/VC-backed companies are mislabelled “in difficulty”, penalizing how innovation is scaled and financed. Invest Europe's response highlights the need to update the rules to reflect real-world business models, to unlock investment, reduce distortions, and support the EU’s competitiveness where it matters most.

The 2025 Invest Europe ESG Reporting Template is a voluntary tool for members and non-members, designed to provide a harmonised and unified set of ESG reporting KPIs at the portfolio company, GP, and fund levels.

Global and regional risk ratings for 2026. A tool for businesses, investors and strategists navigating international markets.

The survey of more than 360 managers and investors highlights improving optimism about activity over the coming year.

A detailed analysis of private equity and venture capital fundraising, investment, and divestment across Europe in the first half of the year.

Europe has the science, talent, and ambition to lead globally in biotech and healthcare, but to secure that leadership and potential, we must build the conditions that make innovation, capital, and people to start, scale and remain in Europe. In this paper, Invest Europe highlights how to strengthen Europe’s biotech and healthcare ecosystem: unlocking investment at every stage, ensuring public funding complements private capital, promoting smarter and harmonised regulation, creating a competitive end-user market for innovation, harnessing technology and data that accelerate discovery, and strengthening the entrepreneurial workforce - to deliver world-class breakthroughs that drive prosperity, resilience, and better health.

As the European Commission, the European Parliament and national governments are about to negotiate the terms of the next EU Budget, this paper shares the perspective of private market players on the role of public funding for private equity ecosystems. It also examines what can be done to ensure that EU citizens’ money is used in the most efficient way to promote the Union’s goals.

The existence of 28 different company law and corporate governance rulebooks in Europe is considered by the Commission as one of the main barriers to a Capital Markets Union. As a result, further reviews of the Accounting Directives and other relevant pieces of legislation in this field are expected over the next few years.

Public funding has long been relevant to the development of the private equity and venture capital ecosystem. National legislative programmes aim at supporting innovation through venture and growth capital, under EU state aid rules.